Dapagliflozin and saxagliptin and Indinavir Sulfate
Determining the interaction of Dapagliflozin and saxagliptin and Indinavir Sulfate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Indinavir may increase the blood levels and effects of sAXagliptin. This may increase the risk of hypoglycemia (low blood sugar). Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, weakness, tremor, nausea, hunger, sweating, and fast or pounding heartbeats. You may need a dose adjustment if you have been taking sAXagliptin and are starting treatment with indinavir. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly alter the plasma concentrations of saxagliptin and its pharmacologically active metabolite, both of which are substrates of the isoenzyme. In one study, administration of a single 100 mg dose of saxagliptin in combination with the potent inhibitor ketoconazole (200 mg every 12 hours at steady state) resulted in increases to saxagliptin peak plasma concentration (Cmax) by 62% and systemic exposure (AUC) by 2.5-fold. These changes were accompanied by corresponding decreases in the Cmax and AUC of the active metabolite by 95% and 88%, respectively. The pharmacokinetics of ketoconazole were not significantly affected, with Cmax and AUC decreasing by just 16% and 13%, respectively. In another study, saxagliptin Cmax increased by 2.4-fold and AUC increased by 3.7-fold during coadministration of a single 20 mg dose of saxagliptin with ketoconazole (200 mg every 12 hours at steady state), while Cmax and AUC of the active metabolite decreased by 96% and 90%, respectively. However, some authorities suggest that these pharmacokinetic effects on saxagliptin and its metabolite are not clinically meaningful.
MANAGEMENT: Some authorities advise against using saxagliptin in combination with potent CYP450 3A4 inhibitors. Other authorities recommend that the dosage of saxagliptin should be limited to 2.5 mg once daily when used with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.
- "Product Information. Onglyza (saxagliptin)." Bristol-Myers Squibb, Princeton, NJ.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: dapagliflozin / saxagliptin
Brand name: Qtern
Synonyms: Dapagliflozin and Saxagliptin
Generic Name: indinavir
Brand name: Crixivan
Synonyms: Indinavir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dapagliflozin and saxagliptin-Indiomin MB
- Dapagliflozin and saxagliptin-Indium 111 Oxyquinoline
- Dapagliflozin and saxagliptin-Indium DTPA
- Dapagliflozin and saxagliptin-Indium In-111 Pentetreotide
- Dapagliflozin and saxagliptin-Indium Oxyquinoline
- Dapagliflozin and saxagliptin-Indocid
- Indinavir Sulfate-Dapagliflozin Propanediol
- Indinavir Sulfate-Dapsone
- Indinavir Sulfate-Dapsone (Systemic)
- Indinavir Sulfate-Dapsone Gel
- Indinavir Sulfate-Dapsone topical
- Indinavir Sulfate-Daptacel